Allergy Therapeutics (AGY) Stock Overview
A commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
AGY Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Allergy Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.067 |
| 52 Week High | UK£0.12 |
| 52 Week Low | UK£0.06 |
| Beta | 0.87 |
| 1 Month Change | -20.00% |
| 3 Month Change | -37.78% |
| 1 Year Change | -18.55% |
| 3 Year Change | 236.00% |
| 5 Year Change | -73.65% |
| Change since IPO | -90.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| AGY | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 1.8% | -5.8% | -1.7% |
| 1Y | -18.5% | 22.8% | 15.5% |
Return vs Industry: AGY underperformed the UK Pharmaceuticals industry which returned 22.8% over the past year.
Return vs Market: AGY underperformed the UK Market which returned 15.5% over the past year.
Price Volatility
| AGY volatility | |
|---|---|
| AGY Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.8% |
Stable Share Price: AGY's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: AGY's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 584 | Manuel Llobet | www.allergytherapeutics.com |
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus.
Allergy Therapeutics plc Fundamentals Summary
| AGY fundamental statistics | |
|---|---|
| Market cap | UK£424.28m |
| Earnings (TTM) | -UK£48.17m |
| Revenue (TTM) | UK£57.29m |
Is AGY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGY income statement (TTM) | |
|---|---|
| Revenue | UK£57.29m |
| Cost of Revenue | UK£27.38m |
| Gross Profit | UK£29.92m |
| Other Expenses | UK£78.09m |
| Earnings | -UK£48.17m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0076 |
| Gross Margin | 52.22% |
| Net Profit Margin | -84.08% |
| Debt/Equity Ratio | 474.5% |
How did AGY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/10 17:41 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Allergy Therapeutics plc is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Adam McCarter | Cavendish |
| Paul Cuddon | Peel Hunt LLP |
| Mohammad Fazeli | Piper Sandler Companies |